GlaxoSmithKline Pharmaceuticals Limited has submitted a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This certificate, received from Kfin Technologies Limited, the company's Registrar and Share Transfer Agent, pertains to the quarter ended March 31, 2026. The certificate confirms that securities received from depository participants for dematerialisation during the specified quarter were processed and listed on the stock exchanges. It also states that the security certificates received for dematerialisation have been duly verified, mutilated, and cancelled, with the depositories' names substituted in the register of members within the stipulated 30-day period. The company has informed BSE Limited and The National Stock Exchange of India Limited about this submission and requested them to take the intimation on record. The announcement was broadcast on April 9, 2026.
